Clinical Trial Update: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intermittent ADT with apalutamide monotherapy in metastatic castration-sensitive prostate cancer (mCSPC) is active but not currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-sensitive Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Castrate-sensitive Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING